NEW YORK — Women's health diagnostic firm Progenity announced after the close of the market on Monday a 38 percent year-over-year increase in third quarter revenues as test volumes ticked up 12 percent.
For the three-month period ended Sept. 30, Progenity reported $25.9 million in revenue, up from $18.8 million in the year-ago quarter but short of the consensus Wall Street estimate of $34.7 million.